New hope for tough gout: experimental combo targets stubborn cases
NCT ID NCT06298071
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new injectable drug called peguricase, given together with methotrexate, in 36 adults with gout that standard treatments cannot control. The main goals are to check safety, how the drug moves through the body, and whether it helps lower uric acid. Participants must be 18-70 years old and not in an acute flare at screening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Bengbu Medical College
RECRUITINGBengbu, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••